Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Debt (2022 - 2025)

Historic Total Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $187.6 million.

  • Axsome Therapeutics' Total Debt fell 26.1% to $187.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.6 million, marking a year-over-year decrease of 26.1%. This contributed to the annual value of $189.0 million for FY2024, which is 244.91% up from last year.
  • Axsome Therapeutics' Total Debt amounted to $187.6 million in Q3 2025, which was down 26.1% from $187.5 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Total Debt high stood at $190.0 million for Q1 2025, and its period low was $49.3 million during Q1 2022.
  • In the last 4 years, Axsome Therapeutics' Total Debt had a median value of $184.5 million in 2023 and averaged $157.9 million.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 21151.23% in 2023, then decreased by 26.1% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Total Debt stood at $100.2 million in 2022, then surged by 84.18% to $184.5 million in 2023, then increased by 2.45% to $189.0 million in 2024, then fell by 0.72% to $187.6 million in 2025.
  • Its last three reported values are $187.6 million in Q3 2025, $187.5 million for Q2 2025, and $190.0 million during Q1 2025.